Nuvation Bio Inc
NUVB2.258USD
+0.028+1.24%
交易中 （美東）報價延遲15分鐘
767.26M總市值
虧損本益比TTM
關於 Nuvation Bio Inc 公司
Nuvation Bio Inc. 是一家生物製藥公司。該公司致力於通過開發差異化和治療候選藥物來解決腫瘤學中未滿足的需求。該公司正在推進多個臨牀階段候選藥物，包括 ROS1 抑制劑、突變異檸檬酸脫氫酶 1 (mIDH1) 抑制劑、溴結構域和額外末端 (BET) 抑制劑以及藥物-藥物偶聯物 (DDC)。其開發候選藥物組合包括塔雷替尼 (ROS1)、沙夫西地尼 (mIDH1)、NUV-868 (BET) 和 NUV-1511 (DDC)。塔雷替尼是一種口服、強效、中樞神經系統活性、選擇性 ROS1 抑制劑，專爲治療 ROS1 陽性非小細胞肺癌 (NSCLC) 而設計。 Safusidenib 是一種口服的強效靶向 mIDH1 抑制劑，目前正在全球 II 期試驗中對低級別 IDH1 突變型膠質瘤患者進行評估。NUV-868 是一種 BD2 選擇性口服小分子 BET 抑制劑，可抑制 BRD4。該公司正在對 NUV-1511 進行 I/II 期研究。
公司簡介
公司代碼NUVB
公司名稱Nuvation Bio Inc
上市日期Jul 01, 2020
CEODr. David T. Hung, M.D.
員工數量220
證券類型Ordinary Share
年結日Jul 01
公司地址357 Tehama Street, Floor 3
城市SAN FRANCISCO
上市交易所NYSE Consolidated
國家United States of America
郵編94103
電話14157543517
網址https://www.nuvationbio.com/
公司代碼NUVB
上市日期Jul 01, 2020
CEODr. David T. Hung, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
持股股東
持股股東
佔比
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
股東類型
持股股東
佔比
Investment Advisor
30.97%
Individual Investor
19.30%
Hedge Fund
12.40%
Investment Advisor/Hedge Fund
9.48%
Venture Capital
8.02%
Research Firm
1.03%
Bank and Trust
0.20%
Pension Fund
0.17%
Private Equity
0.01%
Other
18.42%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
340
277.65M
81.60%
-29.03M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
2023Q2
286
199.03M
91.34%
-20.86M
2023Q1
290
197.27M
90.57%
-23.29M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Hung (David T)
60.28M
17.72%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.03M
14.7%
+5.31M
+11.88%
Mar 31, 2025
Decheng Capital LLC
25.95M
7.63%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.87M
4.66%
-60.61K
-0.38%
Mar 31, 2025
The Vanguard Group, Inc.
15.34M
4.51%
-334.75K
-2.14%
Mar 31, 2025
Omega Fund Management, LLC
13.07M
3.84%
--
--
Mar 31, 2025
Laurion Capital Management LP
9.87M
2.9%
+3.38M
+52.06%
Mar 31, 2025
Octagon Capital Advisors LP
7.90M
2.32%
-1.30M
-14.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.13M
1.51%
+179.41K
+3.62%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
1.43%
+256.02K
+5.57%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
SPDR S&P Pharmaceuticals ETF
0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.63%
ALPS Medical Breakthroughs ETF
0.45%
iShares U.S. Pharmaceuticals ETF
0.25%
iShares Micro-Cap ETF
0.11%
iShares Health Innovation Active ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.97%
SPDR S&P Pharmaceuticals ETF
佔比0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.63%
ALPS Medical Breakthroughs ETF
佔比0.45%
iShares U.S. Pharmaceuticals ETF
佔比0.25%
iShares Micro-Cap ETF
佔比0.11%
iShares Health Innovation Active ETF
佔比0.08%
Avantis US Small Cap Equity ETF
佔比0.06%
iShares Biotechnology ETF
佔比0.05%
Fidelity Enhanced Small Cap ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
